Vol. 70 No. 4 (2024), REVIEWS

Vol. 70 No. 4 (2024)

Atypical Teratoid/Rhabdoid Tumors of Central Nervous System in Children. Literature Re-view

REVIEWS

https://doi.org/10.37469/0507-3758-2024-70-4-622-632

Published 06.09.2024

Elizaveta Vladimirovna Tyurina⁺⁻
Timur T. Valiev⁺⁻
Ella Vyacheslavovna Kumirova⁺⁻
Olga Mikhailovna Romantsova⁺⁻
Svetlana Rafaelevna Varfolomeeva⁺⁻

Elizaveta Vladimirovna Tyurina

N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia

https://orcid.org/0000-0003-4019-5247

Timur T. Valiev

N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, Mos-cow, Russia

https://orcid.org/0000-0002-1469-2365

Ella Vyacheslavovna Kumirova

Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow

https://orcid.org/0000-0001-6125-2410

Olga Mikhailovna Romantsova

N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

https://orcid.org/0000-0002-2310-0106

Svetlana Rafaelevna Varfolomeeva

N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

https://orcid.org/0000-0001-6131-1783

pdf (Русский)

Keywords

atypical teratoid/rhabdoid tumors
tumors of the central nervous system
young children
treatment

How to Cite

Tyurina, E. V., Valiev, T. T., Kumirova, E. V., Romantsova, O. M., & Varfolomeeva, S. R. (2024). Atypical Teratoid/Rhabdoid Tumors of Central Nervous System in Children. Literature Re-view. Voprosy Onkologii, 70(4), 622–632. https://doi.org/10.37469/0507-3758-2024-70-4-622-632

Abstract

Atypical teratoid/rhabdoid tumors (ATRT) are highly aggressive malignant tumors of the central nervous system (CNS), predominantly diagnosed in young children. Despite complex treatment approaches including surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy, outcomes remain extremely unfavorable. Modern epidemiological and molecular biological research aims to study the etiology of tumors, the molecular characteristics of malignant neoplasms, and to determine the possibility of using targeted drugs, which will help to increase the understanding of the structure of the process and give a chance of improving the survival of patients with ATRT.

https://doi.org/10.37469/0507-3758-2024-70-4-622-632

pdf (Русский)

References

Fossey M., Li H., Afzal S., et al. Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. J Neurooncol. 2017; 132(1): 155-62.-DOI: https://doi.org/10.1007/s11060-016-2353-0.

Judkins A.R., Eberhart C.G., Wesseling P. Atypical teratoid/rhabdoid tumor. In: World Health Organization classification of tumors: pathology and genetics of central nervous system. Lyon: IARC Press. 2007: 147-149.

Nesvick C.L., Lafay-Cousin L., Raghunathan A., et al. Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics. J Neurooncol. 2020; 150(1): 47-56.-DOI: https://doi.org/10.1007/s11060-020-03639-w.

Fruwald M., Hasselblatt M., Nemes K., et al. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro Oncol. 2019; 22(7): 1006-17.-DOI: https://doi.org/10.1093/neuonc/noz244.

Nemes K. Infants and newborns with atypical teratoid rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors (eMRT) in the EU-RHAB registry: a unique and challenging population. Cancers. 2022; 14(9): 2185.-DOI: https://doi.org/10.3390/cancers14092185.

Upadhyaya S.A., Robinson G.W., Thomaset A.O. Relevance of molecular groups in children with newly diagnosed atypical teratoid rhabdoid tumor: results from prospective st. jude multi-institutional trials. Clin Cancer Res. 2021; 27(10): 2879-2889.-DOI: https://doi.org/10.1158/1078-0432.CCR-20-4731.

McNeill K.A. Epidemiology of brain tumors. Neurol Clin. 2016; 34(4): 981-98.-DOI: https://doi.org/10.1016/j.ncl.2016.06.014.

Ostrom Q., Patil N., Cioffi G., et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020; 22(Supplement_1): iv1–96.-DOI: https://doi.org/10.1093/neuonc/noaa200.

Louis D., Perry A., Reifeberger G., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803-20.-DOI: https://doi.org/10.1007/s00401-016-1545-1.

Cosnarovici M.M., Cosnarovici R.V., Piciu D. Updates of the 2016 World Health Organization Classification of Pediatric Tumors of the Central Nervous System - a systematic review. Med Pharm Rep. 2021; 94(3): 282-8.-DOI: https://doi.org/10.15386/mpr-1811.

Louis D., Perry A., Wesseling P., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231-51.-DOI: https://doi.org/10.1093/neuonc/noab106.

Rushing E.J. WHO classification of tumors of the nervous system: preview of the upcoming 5th edition. MEMO. 2021; 14(2): 188-91.-DOI: https://doi.org/10.1007/s12254-021-00680-x.

Ольхова Л.В. Прогностические факторы и влияние высокодозной полихимиотерапии с аутологичной трансплантацией гемопоэтических стволовых клеток на результаты лечения атипичных тератоид-рабдоидных опухолей центральной нервной системы у детей. Диссертация на соискание ученой степени кандидата медицинских наук. Федеральное государственное бюджетное учреждение «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства». 2022; 169. URL: https://www.1spbgmu.ru/images/home/universitet/Struktura/Soveti_i_Komissii/Dissertacii/%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0/%D0%9A%D0%B0%D0%BD%D0%B4.%D0%B4%D0%B8%D1%81%D1%81%D0%B5%D1%80%D1%82%D0%B0%D1%86%D0%B8%D1%8F_%D0%90%D0%A2%D0%A0%D0%9E_%D0%A6%D0%9D%D0%A1_%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0_%D0%9B.pdf. [Olkhova L.V. Prognostic factors and the influence of high-dosed polychemotherapy with autologous stem cell transplantation on treatment results of pediatric atypical teratoid/rhabdoid tumors of central nervous system. Dissertation for the degree of Candidate of Medical Sciences. FSBI «Russian Research Institute of Hematology and Transfusiology of the Federal Medical-Biological Agency». 2022; 169. 2022; 169. URL: https://www.1spbgmu.ru/images/home/universitet/Struktura/Soveti_i_Komissii/Dissertacii/%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0/%D0%9A%D0%B0%D0%BD%D0%B4.%D0%B4%D0%B8%D1%81%D1%81%D0%B5%D1%80%D1%82%D0%B0%D1%86%D0%B8%D1%8F_%D0%90%D0%A2%D0%A0%D0%9E_%D0%A6%D0%9D%D0%A1_%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0_%D0%9B.pdf (in Rus)].

Torchia J., Golbourn B., Feng S., et al. Integrated (epi)-genomic analyses iden- tify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell. 2016; 30: 891-908.-DOI: https://doi.org/10.1016/j. ccell.2016.11.003.

Frühwald M.C., Graf N. European Rhabdoid Registry. A multinational registry for rhabdoid tumors of any anatomical site V2.2010. 2010; 398. URL: https://www.orpha.net/pdfs/data/prj/DE/Reg77865GB.pdf.

Zimmerman M.A., Turner Ch., Chordas Ch., et al. Chemo/radiation therapy for CNS AT/RT. Version 1.7/6-9-2006.

Park M., Han J.W., Hahn S.M., et al. Atypical teratoid/rhabdoid tumor of the central nervous system in children under the age of 3 years. Cancer Res Treat. 2021; 53(2): 378-88.-DOI: https://doi.org/10.4143/crt.2020.756.

Zhang C., Li H. Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors. Pediatr Investig. 2022; 6(2): 111-22.-DOI: https://doi.org/10.1002/ped4.12325.

Tran H.M., Wu K.S., Sung S.Y., et al. Upregulation of protein synthesis and proteasome degradation confers sensitivity to proteasome inhibitor borte- zomib in myc-atypical teratoid/rhabdoid tumors. Cancers. 2020; 12.-DOI: https://doi.org/10.3390/cancers12030752.

Kim S.H. Yesterdays, todays, and tomorrows – Korean Society for Pediatric Neuro-Oncology. Brain Tumor Res Treat. 2023; 11(3): 177-182.-DOI: https://doi.org/10.14791/btrt2023.0018.

Slavc I., Chocholous M., Leiss U., et al. Atypical teratoid rhabdoid tumor: improved long‐term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012. Cancer Med. 2013; 3(1): 91-100.-DOI: https://doi.org/10.1002/cam4.161.

Ольхова Л.В., Кушель Ю.В., Кадыров Ш.У., et al. Влияние радикальности оперативного вмешательства на результаты лечения атипичной тератоидно-рабдоидной опухоли центральной нервной системы у детей. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2021; 85(2): 17‑25. [Olkhova L.V, Kushel Yu.V., Kadyrov Sh.U. et al. The influence of radical surgery on treatment results of pediatric atypical teratoid/rhabdoid tumors of central nervous system. Burdenko's Journal of Neurosurgery. 2021; 85(2): 17-25. (in Rus)].

Kerl K., Ries D., Unland R., et al. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer. 2013; 13: 286.-DOI: https://doi.org/10.1186/1471-2407-13-286.

Zhang C., Li H. Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors. Pediatr Investig. 2022; 6: 111-122.-DOI: https://doi.org/10.1002/ped4.12325.

Tran H.M., Wu K.S., Sung S.Y. et al. Upregulation of protein synthesis and proteasome degradation confers sensitivity to proteasome inhibitor borte- zomib in myc-atypical teratoid/rhabdoid tumors. Cancers. 2020;12. DOI: https://doi.org/10.3390/cancers12030752.

Alimova I. ATRT-01. PARP Inhibition as a therapeutic target in ATRO. Neuro Oncol. 2023; 25(Suppl 1): i1.-DOI: https://doi.org/10.1093/neuonc/noad073.001.

Zhibin Li. Atypical teratoid/rhabdoid tumor with CDK6 amplification in a child: a case report and literature review. Front Pediatr. 2023; 11: 1237572.-DOI: https://doi.org/10.3389/fped.2023.1237572.

Forrest S.J. Genomic and immunologic characterization of INI1-deficien pediatric cancers. Clin Cancer Res. 2020; 26 (12): 288202890.-DOI: https://doi.org/10.1158/1078-0432.CCR-19-3089.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.